BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9066006)

  • 1. Inhibition of urokinase-type plasminogen activator (uPA) abrogates myogenesis in vitro.
    Muñoz-Cánoves P; Miralles F; Baiget M; Félez J
    Thromb Haemost; 1997 Mar; 77(3):526-34. PubMed ID: 9066006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activators and their inhibitors in the neuromuscular system: I. Developmental regulation of plasminogen activator isoforms during in vitro myogenesis in two cell lines.
    Festoff BW; Rao JS; Maben C; Hantaï D
    J Cell Physiol; 1990 Aug; 144(2):262-71. PubMed ID: 2199466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells.
    Sasaki CY; Lin H; Passaniti A
    J Cell Physiol; 1999 Oct; 181(1):1-13. PubMed ID: 10457348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion.
    Jarrard DF; Hansen NM; Patai B; Rukstalis DB
    Invasion Metastasis; 1995; 15(1-2):34-45. PubMed ID: 7672930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage.
    Wohn KD; Kanse SM; Deutsch V; Schmidt T; Eldor A; Preissner KT
    Thromb Haemost; 1997 Mar; 77(3):540-7. PubMed ID: 9066008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
    Mohanam S; Jasti SL; Kondraganti SR; Chandrasekar N; Kin Y; Fuller GN; Lakka SS; Kyritsis AP; Dinh DH; Olivero WC; Gujrati M; Yung WK; Rao JS
    Clin Cancer Res; 2001 Aug; 7(8):2519-26. PubMed ID: 11489835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
    Teesalu T; Blasi F; Talarico D
    Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin.
    Smith PC; Santibañez JF; Morales JP; Martinez J
    J Periodontal Res; 2004 Dec; 39(6):380-7. PubMed ID: 15491342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
    Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
    Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The levels of vascular smooth as well as skeletal muscle actin mRNAs differ substantially among both myoblast and fibroblast lines with different skeletal myogenic potentials.
    Sharp SB; Vazquez A; Theimer M; Silva DK; Muscati SR; Sylber M; Mogassa M
    Cell Mol Biol (Noisy-le-grand); 1992 Dec; 38(8):903-13. PubMed ID: 1477607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
    Kiyan J; Smith G; Haller H; Dumler I
    Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T
    Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C; Moses EK; Quinn MA; Rice GE
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.